Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Stem-cell transplant performed status

Time frame: Baseline

Medical history by system-organ-class, preferred term from CML diagnosis to asciminib start date

Time frame: Baseline

Overall tyrosine kinase inhibitors (TKIs) prior to index date

Time frame: Baseline

Prior TKIs between CML diagnosis and T315I mutation diagnosis

Time frame: Baseline

Prior TKIs between T315I mutation diagnosis and index date

Time frame: Baseline

Sequence of prior TKI treatment patterns

Time frame: Baseline

Number of patients with response to prior TKIs from CML diagnosis to asciminib (index date)

Response types were MMR, CCyR, and CHR.

Time frame: Baseline

Number of patients with response to prior TKIs between CML diagnosis to T315I mutation diagnosis

Response types were MMR, CCyR, and CHR.

Time frame: Baseline

Number of patients with response to prior TKIs between T315I mutation diagnosis to asciminib start (index date)

Response types were MMR, CCyR, and CHR.

Time frame: Baseline

Number of patients with intolerance to prior TKIs, per category

Categories were discontinuation due to adverse events, relationship to treatment, and outcome.

Time frame: Baseline

Number of patients with intolerance to last TKI prior to asciminib, per category

Categories were discontinuation due to adverse events, relationship to treatment, and outcome.

Time frame: Baseline

Asciminib dose

Time frame: Up to 13 months

Asciminib discontinuation

Time frame: Up to 13 months

Duration of exposure to asciminib

Time frame: Up to 13 months